Podoplanin: An emerging cancer biomarker and therapeutic target

Harini Krishnan; Julie Rayes; Tomoyuki Miyashita; Genichiro Ishii; Edward P. Retzbach; Stephanie A. Sheehan; Ai Takemoto; Yao Wen Chang; Kazue Yoneda; Jun Asai; Lasse Jensen; Lushun Chalise; Atsushi Natsume; Gary S. Goldberg

doi:10.1111/cas.13580

Podoplanin: An emerging cancer biomarker and therapeutic target

Harini Krishnan
, Julie Rayes
, Tomoyuki Miyashita
, Genichiro Ishii
, Edward P. Retzbach
, Stephanie A. Sheehan
, Ai Takemoto
, Yao Wen Chang
, Kazue Yoneda
, Jun Asai
, Lasse Jensen
, Lushun Chalise
, Atsushi Natsume
, Gary S. Goldberg

Molecular Biology

Rowan University

Research output: Contribution to journal › Review article › peer-review

52 Scopus citations

Abstract

Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

Original language	English (US)
Pages (from-to)	1292-1299
Number of pages	8
Journal	Cancer Science
Volume	109
Issue number	5
DOIs	https://doi.org/10.1111/cas.13580
State	Published - May 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1111/cas.13580

Cite this

@article{0c96dd1606de4949b284a04be63e638e,

title = "Podoplanin: An emerging cancer biomarker and therapeutic target",

abstract = "Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.",

author = "Harini Krishnan and Julie Rayes and Tomoyuki Miyashita and Genichiro Ishii and Retzbach, \{Edward P.\} and Sheehan, \{Stephanie A.\} and Ai Takemoto and Chang, \{Yao Wen\} and Kazue Yoneda and Jun Asai and Lasse Jensen and Lushun Chalise and Atsushi Natsume and Goldberg, \{Gary S.\}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer Science published by John Wiley \& Sons Australia, Ltd on behalf of Japanese Cancer Association.",

year = "2018",

month = may,

doi = "10.1111/cas.13580",

language = "English (US)",

volume = "109",

pages = "1292--1299",

journal = "Cancer Science",

issn = "1347-9032",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - Podoplanin

T2 - An emerging cancer biomarker and therapeutic target

AU - Krishnan, Harini

AU - Rayes, Julie

AU - Miyashita, Tomoyuki

AU - Ishii, Genichiro

AU - Retzbach, Edward P.

AU - Sheehan, Stephanie A.

AU - Takemoto, Ai

AU - Chang, Yao Wen

AU - Yoneda, Kazue

AU - Asai, Jun

AU - Jensen, Lasse

AU - Chalise, Lushun

AU - Natsume, Atsushi

AU - Goldberg, Gary S.

PY - 2018/5

Y1 - 2018/5

N2 - Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

AB - Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

UR - https://www.scopus.com/pages/publications/85047848192

UR - https://www.scopus.com/pages/publications/85047848192#tab=citedBy

U2 - 10.1111/cas.13580

DO - 10.1111/cas.13580

M3 - Review article

C2 - 29575529

SN - 1347-9032

VL - 109

SP - 1292

EP - 1299

JO - Cancer Science

JF - Cancer Science

IS - 5

ER -

Podoplanin: An emerging cancer biomarker and therapeutic target

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this